stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) Return on equity
RadNet, Inc.'s return on equity over the twelve months to 30 June 2026 was −1.64%, down 0.1 percentage points from fiscal 2025 (−1.50%). Over the past ten years it has ranged from −6.04% (fiscal 2020) to 34.9% (fiscal 2015); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −1.50% | (1.79) |
| FY2024 | 0.29% | (0.18) |
| FY2023 | 0.47% | (2.07) |
| FY2022 | 2.54% | (5.64) |
| FY2021 | 8.18% | 14.22 |
| FY2020 | −6.04% | (12.85) |
| FY2019 | 6.81% | (17.06) |
| FY2018 | 23.9% | 23.78 |
| FY2017 | 0.09% | (16.25) |
| FY2016 | 16.3% | (18.57) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CDNA CareDx, Inc. compare | 33.0% |
| SHC Sotera Health Company compare | 27.0% |
| QGEN QIAGEN N.V. compare | 11.9% |
| VCYT Veracyte, Inc. compare | 9.43% |
| ICLR ICON PLC compare | 4.86% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| RDNT RadNet, Inc. | −1.64% |
| GRAL GRAIL, Inc. compare | −17.3% |
| ADPT Adaptive Biotechnologies Corporation compare | −36.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement